1.Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease
Shang-Chin HUANG ; Hau-Jyun SU ; Jia-Horng KAO ; Tai-Chung TSENG ; Hung-Chih YANG ; Tung-Hung SU ; Pei-Jer CHEN ; Chun-Jen LIU
Gut and Liver 2021;15(3):451-458
Background/Aims:
Fatty liver disease is defined as a cluster of diseases with heterogeneous etiologies, and its definition continues to evolve. The novel conceptional criteria for metabolic dysfunction-associated fatty liver disease (MAFLD) were proposed in 2020 to avoid the exclusion of a certain subpopulation, but their evaluations have been limited. We aimed to examine and compare the clinical as well as histologic features of MAFLD versus nonalcoholic fatty liver disease (NAFLD) in patients with biopsy-proven hepatic steatosis.
Methods:
From January 2009 to December 2019, 175 patients with histology-proven hepatic steatosis and 10 with cryptogenic cirrhosis who were treated at National Taiwan University Hospital, Taipei, Taiwan, were enrolled. Patients were classified into different groups according to the diagnostic criteria of MAFLD and NAFLD. The clinical and histologic features were then analyzed and compared.
Results:
In total, 76 patients (41.1%) were diagnosed with both MAFLD and NAFLD, 81 patients (43.8%) were diagnosed with MAFLD alone, nine patients (4.9%) were diagnosed with NAFLD alone, and 19 patients (10.3%) were diagnosed with neither. Those with MAFLD alone exhibited a higher degree of disease severity regarding histology and laboratory data than those with NAFLD alone. Advanced fibrosis was associated with the presences of hepatitis B virus infection and metabolic diseases.
Conclusions
The novel diagnostic criteria for MAFLD include an additional 38.9% of patients with hepatic steatosis and can better help identify those with a high degree of disease severity for early intervention than can the previous NAFLD criteria.
2.Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease
Shang-Chin HUANG ; Hau-Jyun SU ; Jia-Horng KAO ; Tai-Chung TSENG ; Hung-Chih YANG ; Tung-Hung SU ; Pei-Jer CHEN ; Chun-Jen LIU
Gut and Liver 2021;15(3):451-458
Background/Aims:
Fatty liver disease is defined as a cluster of diseases with heterogeneous etiologies, and its definition continues to evolve. The novel conceptional criteria for metabolic dysfunction-associated fatty liver disease (MAFLD) were proposed in 2020 to avoid the exclusion of a certain subpopulation, but their evaluations have been limited. We aimed to examine and compare the clinical as well as histologic features of MAFLD versus nonalcoholic fatty liver disease (NAFLD) in patients with biopsy-proven hepatic steatosis.
Methods:
From January 2009 to December 2019, 175 patients with histology-proven hepatic steatosis and 10 with cryptogenic cirrhosis who were treated at National Taiwan University Hospital, Taipei, Taiwan, were enrolled. Patients were classified into different groups according to the diagnostic criteria of MAFLD and NAFLD. The clinical and histologic features were then analyzed and compared.
Results:
In total, 76 patients (41.1%) were diagnosed with both MAFLD and NAFLD, 81 patients (43.8%) were diagnosed with MAFLD alone, nine patients (4.9%) were diagnosed with NAFLD alone, and 19 patients (10.3%) were diagnosed with neither. Those with MAFLD alone exhibited a higher degree of disease severity regarding histology and laboratory data than those with NAFLD alone. Advanced fibrosis was associated with the presences of hepatitis B virus infection and metabolic diseases.
Conclusions
The novel diagnostic criteria for MAFLD include an additional 38.9% of patients with hepatic steatosis and can better help identify those with a high degree of disease severity for early intervention than can the previous NAFLD criteria.
3.Alcohol Celiac Plexus Block for Upper Abdominal Cancer Pain .
Hung Kun OH ; Yang Sik SHIN ; Yong Aee CHUN
Korean Journal of Anesthesiology 1979;12(4):407-413
Celiac plexus block for upper abdominal cancer pain was performed on 26 patients from April, 1977 to April, ]979 at the Pain Clinic of Yonsei Medical Center. Patients were placed in prone position and the location of the tip of needles was conformed by fluoroscopy and on image intensifier. Immediately after the assesment of the effect of test blocks with 1% lidocaine, permaneat blocks with 50% aIcohol were performed. The results obtained were as follows: 1} Under flouroscopic control, the interval from the test to the permanent block was less than 15 min, thus economical in both time and expense. Also no patient refused the alcohol block after the test block and alcohol injection was painless. 2) The test and permanent blocks were effective in all cases, but repeated permanent block was necessary in 7 cases within 2 weeks after the initial alcohol block. 3) As to complications, hypotension, nausea and face flushing developed in 10, 3 and 8 cases respectively. There were no postponements and no mortality. 4) These cases were discharged from hospital without pain 2 to 18 days after block. 5) Two cases with recurrent cancer pain had repeated alcohol block with excellent effect 3 and 6 months after the initial alcohol block. 6) The block to death interval was l to 4 months in 6 cases in which follow up was possible. From the above results. we may conclude that by using fluoroscopyic control with needle placement only once, the test and permanent blocks were performed safely, effectively and painlessly.
Celiac Plexus*
;
Equidae
;
Fluoroscopy
;
Flushing
;
Follow-Up Studies
;
Humans
;
Hypotension
;
Lidocaine
;
Mortality
;
Nausea
;
Needles
;
Pain Clinics
;
Prone Position
4.FDG PET or PET/CT in Evaluation of Renal Angiomyolipoma.
Chun Yi LIN ; Hui Yi CHEN ; Hueisch Jy DING ; Kuo Yang YEN ; Chia Hung KAO
Korean Journal of Radiology 2013;14(2):337-342
OBJECTIVE: Angiomyolipoma is the most common benign kidney tumor. However, literature describing FDG PET findings on renal angiomyolipoma (AML) is limited. This study reports the FDG PET and PET/CT findings of 21 cases of renal AML. MATERIALS AND METHODS: The study reviews FDG PET and PET/CT images of 21 patients diagnosed with renal AML. The diagnosis is based on the classical appearance of an AML on CT scan with active surveillance for 6 months. The study is focused on the observation of clinical and radiographic features. RESULTS: Six men and 15 women were included in our study. The mean age of the patients was 57.14 +/- 9.67 years old. The mean diameter of 21 renal AML on CT scans was 1.76 +/- 1.00 cm (Min: 0.6 cm; Max: 4.4 cm). CT scans illustrated renal masses typical of AMLs, and the corresponding FDG PET scans showed minimal FDG activities in the area of the tumors. None of the 21 AMLs showed a maximum standardized uptake value (SUVmax) greater than 1.98. No statistically significant correlation was present between SUVmax and tumor size. CONCLUSION: Renal AMLs demonstrate very low to low uptake on FDG PET and PET/CT imaging in this study. When a fat-containing tumor in the kidney is found on a CT scan, it is critical to differentiate an AML from a malignant tumor including an RCC, liposarcoma, and Wilms tumor. This study suggests that FDG PET or PET/CT imaging is useful for differentiating a renal AML from a fat-containing malignant tumor.
Angiomyolipoma/*radionuclide imaging
;
Contrast Media/diagnostic use
;
Ehlers-Danlos Syndrome
;
Female
;
Fluorodeoxyglucose F18/diagnostic use
;
Humans
;
Kidney Neoplasms/*radionuclide imaging
;
Male
;
Middle Aged
;
*Positron-Emission Tomography
;
*Positron-Emission Tomography and Computed Tomography
;
Radiopharmaceuticals/diagnostic use
;
Retrospective Studies
5.Mesenchymal Stem Cell Secreted-Extracellular Vesicles are Involved in Chondrocyte Production and Reduce Adipogenesis during Stem Cell Differentiation
Yu-Chen TSAI ; Tai-Shan CHENG ; Hsiu-Jung LIAO ; Ming-Hsi CHUANG ; Hui-Ting CHEN ; Chun-Hung CHEN ; Kai-Ling ZHANG ; Chih-Hung CHANG ; Po-Cheng LIN ; Chi-Ying F. HUANG
Tissue Engineering and Regenerative Medicine 2022;19(6):1295-1310
BACKGROUND:
Extracellular vesicles (EVs) are derived from internal cellular compartments, and have potential as a diagnostic and therapeutic tool in degenerative disease associated with aging. Mesenchymal stem cells (MSCs) have become a promising tool for functional EVs production. This study investigated the efficacy of EVs and its effect on differentiation capacity.
METHODS:
The characteristics of MSCs were evaluated by flow cytometry and stem cell differentiation analysis, and a production mode of functional EVs was scaled from MSCs. The concentration and size of EVs were quantitated by Nanoparticle Tracking Analysis (NTA). Western blot analysis was used to assess the protein expression of exosomespecific markers. The effects of MSC-derived EVs were assessed by chondrogenic and adipogenic differentiation analyses and histological observation.
RESULTS
The range of the particle size of adipose-derived stem cells (ADSCs)- and Wharton’s jelly -MSCs-derived EVs were from 130 to 150 nm as measured by NTA, which showed positive expression of exosomal markers. The chondrogenic induction ability was weakened in the absence of EVs in vitro. Interestingly, after EV administration, type II collagen, a major component in the cartilage extracellular matrix, was upregulated compared to the EV-free condition.Moreover, EVs decreased the lipid accumulation rate during adipogenic induction.
6.Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas
Ting-Yuan LAN ; Yen-Chun LIN ; Tai-Chung TSENG ; Hung-Chih YANG ; Jui-Hung KAO ; Chiao-Feng CHENG ; Tai-Ju LEE ; Shang-Chin HUANG ; Cheng-Hsun LU ; Ko-Jen LI ; Song-Chou HSIEH
Gut and Liver 2023;17(2):288-298
Background/Aims:
Rituximab is known to be associated with high hepatitis B virus (HBV) reactivation rate in patients with resolved HBV infection and hematologic malignancy. However, data regarding HBV reactivation (HBVr) in rheumatic patients receiving rituximab is limited. To assess the HBVr rate in hepatitis B surface antigen (HBsAg)-negative patients receiving rituximab for autoimmune diseases in a large real-world cohort.
Methods:
From March 2006 to December 2019, 900 patients with negative HBsAg receiving at least one cycle of rituximab for autoimmune diseases in a tertiary medical center in Taiwan were retrospectively reviewed. Clinical outcome and factors associated with HBVr were analyzed.
Results:
After a median follow-up period of 3.3 years, 21 patients developed HBVr, among whom 17 patients were positive for hepatitis B core antibody (anti-HBc) and four were negative. Thirteen patients had clinical hepatitis flare, while eight patients had HBsAg seroreversion without hepatitis. Old age, anti-HBc positivity, undetectable serum hepatitis B surface antibody level at rituximab initiation and a higher average rituximab dose were associated with a higher HBVr rate. There was no significant difference in the HBVr risk between rheumatoid arthritis and other autoimmune diseases. Among anti-HBc-negative patients, subjects without HBV vaccination at birth had an increased risk of HBVr (4/368, 1.1%) compared with those who received vaccination (0/126, 0%).
Conclusions
In HBV endemic areas where occult HBV is prevalent, anti-HBc-negative patients, may still be at risk for HBVr after rituximab exposure. HBVr may still be considered in HBsAgnegative patients developing abnormal liver function after rituximab exposure, even in patients with negative anti-HBc.
7.Development and characterization of a potential diagnostic monoclonal antibody against capsid protein VP1 of the chicken anemia virus.
Yi Yang LIEN ; Chi Hung HUANG ; Fang Chun SUN ; Shyang Chwen SHEU ; Tsung Chi LU ; Meng Shiunn LEE ; Shu Chin HSUEH ; Hsi Jien CHEN ; Meng Shiou LEE
Journal of Veterinary Science 2012;13(1):73-79
Chicken anemia virus (CAV) is an important viral pathogen that causes anemia and severe immunodeficiency syndrome in chickens worldwide. In this study, a potential diagnostic monoclonal antibody against the CAV VP1 protein was developed which can precisely recognize the CAV antigen for diagnostic and virus recovery purposes. The VP1 gene of CAV encoding the N-terminus-deleted VP1 protein, VP1Nd129, was cloned into an Escherichia (E.) coli expression vector. After isopropyl-beta-D-thiogalactopyronoside induction, VP1Nd129 protein was shown to be successfully expressed in the E. coli. By performing an enzyme-linked immunoabsorbent assay using two coating antigens, purified VP1Nd129 and CAV-infected liver tissue lysate, E3 monoclonal antibody (mAb) was found to have higher reactivity against VP1 protein than the other positive clones according to the result of limiting dilution method from 64 clones. Using immunohistochemistry, the presence of the VP1-specific mAb, E3, was confirmed using CAV-infected liver and thymus tissues as positive-infected samples. Additionally, CAV particle purification was also performed using an immunoaffinity column containing E3 mAb. The monoclonal E3 mAb developed in this study will not only be very useful for detecting CAV infection and performing histopathology studies of infected chickens, but may also be used to purify CAV particles in the future.
Animals
;
Antibodies, Monoclonal/biosynthesis/genetics/*immunology
;
Antigens, Viral/analysis
;
Capsid Proteins/genetics/*immunology
;
Chicken anemia virus/genetics/*immunology
;
*Chickens
;
Circoviridae Infections/blood/immunology/*veterinary/virology
;
Escherichia coli/genetics
;
Immunohistochemistry/veterinary
;
Liver/virology
;
Mice
;
Mice, Inbred BALB C
;
Microscopy, Fluorescence/veterinary
;
Poultry Diseases/blood/immunology/*virology
;
Specific Pathogen-Free Organisms
;
Thymus Gland/virology
8.Positive Symptoms in Antipsychotic-naïve Schizophrenia are Associated with Increased Body Mass Index after Treatment
Shih-Hsien LIN ; Huai-Hsuan TSENG ; Hsin Chun TSAI ; Mei Hung CHI ; I Hui LEE ; Po See CHEN ; Kao Chin CHEN ; Yen Kuang YANG
Clinical Psychopharmacology and Neuroscience 2021;19(1):155-159
Objective:
Weight gain is an important risk factor for morbidity and mortality among patients with schizophrenia. We speculated that positive symptoms, related to dopaminergic hyperactivity and altered mesolimbic function, are associated with weight gain.
Methods:
Twenty-two antipsychotic-naïve, first-episode patients with schizophrenia were enrolled. The Positive and Negative Syndrome Scale was completed at enrollment and follow-up. Body mass index (BMI) was also measured.
Results:
The increase in BMI, after 6.04 ± 2.16 years of follow-up, was associated with positive symptoms, but not negative symptoms, before treatment with antipsychotics in antipsychotic-naïve patients with schizophrenia.
Conclusion
This finding implied that dopaminergic hyperactivity could be an important factor to predict the treatment outcome. Body weight control is important for the health management of patients with schizophrenia with more severe positive symptoms.
10.Increased Readmission Risk and Healthcare Cost for Delirium Patients without Immediate Hospitalization in the Emergency Department.
I Chun MA ; Kao Chin CHEN ; Wei Tseng CHEN ; Hsin Chun TSAI ; Chien Chou SU ; Ru Band LU ; Po See CHEN ; Wei Hung CHANG ; Yen Kuang YANG
Clinical Psychopharmacology and Neuroscience 2018;16(4):398-406
OBJECTIVE: Hospitalization of patients with delirium after visiting the emergency department (ED) is often required. However, the readmission risk after discharge from the ED should also be considered. This study aimed to explore whether (i) immediate hospitalization influences the readmission risk of patients with delirium; (ii) the readmission risk is affected by various risk factors; and (iii) the healthcare cost differs between groups within 28 days of the first ED visit. METHODS: Using the National Health Insurance Research Database, the data of 2,780 subjects presenting with delirium at an ED visit from 2000 to 2008 were examined. The readmission risks of the groups of patients (i.e., patients who were and were not admitted within 24 hours of an ED visit) within 28 days were compared, and the effects of the severities of different comorbidities (using Charlson’s comorbidity index, CCI), age, gender, diagnosis and differences in medical healthcare cost were analyzed. RESULTS: Patients without immediate hospitalization had a higher risk of readmission within 3, 7, 14, or 28 days of discharge from the ED, especially subjects with more severe comorbidities (CCI≥3) or older patients (≥65 years). Subjects with more severe comorbidities or older subjects who were not admitted immediately also incurred a greater healthcare cost for re-hospitalization within the 28-day follow-up period. CONCLUSION: Patients with delirium with a higher CCI or of a greater age should be carefully considered for immediate hospitalization from ED for further examination in order to reduce the risk of re-hospitalization and cost of healthcare.
Comorbidity
;
Delirium*
;
Delivery of Health Care*
;
Diagnosis
;
Emergencies*
;
Emergency Service, Hospital*
;
Follow-Up Studies
;
Health Care Costs*
;
Hospitalization*
;
Humans
;
National Health Programs
;
Risk Factors